share_log

Cantor Fitzgerald Maintains Overweight on Oncternal Therapeutics, Lowers Price Target to $1.3

Cantor Fitzgerald Maintains Overweight on Oncternal Therapeutics, Lowers Price Target to $1.3

坎托·菲茨杰拉德维持对内科疗法的增持,将目标价下调至1.3美元
Benzinga ·  2023/04/04 07:34

Cantor Fitzgerald analyst Li Watsek maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Overweight and lowers the price target from $4 to $1.3.

坎托·菲茨杰拉德分析师李·沃瑟克维持Oncternal Therapeutics(纳斯达克股票代码:ONCT)的增持,并将目标股价从4美元下调至1.3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发